Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Immunotherapies have revolutionized medical oncology following the remarkable and, in
some cases, unprecedented outcomes observed in certain groups of patients with cancer …

Evasion of immune system is a hallmark of cancer, which enables cancer cells to escape the
attack from immune cells. Cancer cells can express many immune inhibitory signalling …

Checkpoint programmed death-1 (PD-1)/programmed cell death ligands (PD-Ls) have been
identified as negative immunoregulatory molecules that promote immune evasion of tumor …

The programmed death protein 1 (PD-1) and its ligand (PD-L1) represent a well-
characterized immune checkpoint in cancer, effectively targeted by monoclonal antibodies …

Background The efficacy of programmed death-1 blockade in epidermal growth factor
receptor gene (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) patients with …

Recent studies have established that tumors can reprogram the pathways involved in
nutrient uptake and metabolism to withstand the altered biosynthetic, bioenergetics and …

Cancer expression of PD-L1 suppresses anti-tumor immunity. PD-L1 has emerged as a
remarkable therapeutic target. However, the regulation of PD-L1 degradation is not …

Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD‐1) and
programmed death‐ligand 1 (PD‐L1) have improved the survival of patients with non‐small …

Background The ATLANTIC trial reported that higher PD-L1 expression in tumors was
involved in a higher objective response in patients with EGFR+/ALK+ non-small cell lung …